- Home
- DMII vs OMER Comparison
DMII vs OMER Comparison
Compare DMII & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMII | OMER |
|---|---|---|
| Founded | 2024 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 656.4M | 772.8M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | DMII | OMER |
|---|---|---|
| Price | $10.02 | $14.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 166.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $2.95 |
| 52 Week High | $10.02 | $17.65 |
Technical Indicators
Market Signals| Indicator | DMII | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 69.42 |
| Support Level | $9.93 | $10.82 |
| Resistance Level | N/A | $17.65 |
| Average True Range (ATR) | 0.01 | 0.69 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 60.16 | 84.85 |
Price Performance
Historical ComparisonAbout DMII Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp is a blank check Company.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.